Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D04WFL
|
||||
| Former ID |
DAP000391
|
||||
| Drug Name |
Trastuzumab
|
||||
| Synonyms |
Herceptin; Herceptin (TN); Trastuzumab (INN); Trastuzumab (genetical recombination); Trastuzumab (genetical recombination) (JAN); Trastuzumab (ERBB2 mAb inhibitor)
|
||||
| Drug Type |
Antibody
|
||||
| Therapeutic Class |
Anticancer Agents
|
||||
| Company |
Roche; Genentech
|
||||
| Formula |
C6470H10012N1726O2013S42
|
||||
| CAS Number |
CAS 180288-69-1
|
||||
| PubChem Substance ID | |||||
| SuperDrug ATC ID |
L01XC03
|
||||
| SuperDrug CAS ID |
cas=180288691
|
||||
| Drug Resistance Mutation (DRM) | |||||
| DRM | DRM Info | ||||
| Target and Pathway | |||||
| Target(s) | Receptor protein-tyrosine kinase erbB-2 | Target Info | [535355], [535660], [535976] | ||
| KEGG Pathway | ErbB signaling pathway | ||||
| Calcium signaling pathway | |||||
| HIF-1 signaling pathway | |||||
| Focal adhesion | |||||
| Adherens junction | |||||
| Pathways in cancer | |||||
| Proteoglycans in cancer | |||||
| MicroRNAs in cancer | |||||
| Pancreatic cancer | |||||
| Endometrial cancer | |||||
| Prostate cancer | |||||
| Bladder cancer | |||||
| Non-small cell lung cancer | |||||
| Central carbon metabolism in cancer | |||||
| NetPath Pathway | TCR Signaling Pathway | ||||
| PANTHER Pathway | Cadherin signaling pathway | ||||
| EGF receptor signaling pathway | |||||
| PathWhiz Pathway | Phosphatidylinositol Phosphate Metabolism | ||||
| WikiPathways | DNA Damage Response (only ATM dependent) | ||||
| ErbB Signaling Pathway | |||||
| EGF/EGFR Signaling Pathway | |||||
| Focal Adhesion | |||||
| Extracellular vesicle-mediated signaling in recipient cells | |||||
| Bladder Cancer | |||||
| Signaling by ERBB2 | |||||
| Integrated Pancreatic Cancer Pathway | |||||
| Signaling Pathways in Glioblastoma | |||||
| Leptin signaling pathway | |||||
| miR-targeted genes in muscle cell - TarBase | |||||
| Semaphorin interactions | |||||
| References | |||||
| Ref 468150 | (http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 5082). | ||||
| Ref 532651 | 2013 FDA drug approvals. Nat Rev Drug Discov. 2014 Feb;13(2):85-9. | ||||
| Ref 536361 | Natural products as sources of new drugs over the last 25 years. J Nat Prod. 2007 Mar;70(3):461-77. Epub 2007 Feb 20. | ||||
| Ref 535355 | Anti-ErbB-2 monoclonal antibodies and ErbB-2-directed vaccines. Cancer Immunol Immunother. 2002 Jan;50(11):569-87. Epub 2001 Nov 24. | ||||
| Ref 535660 | Knockouts model the 100 best-selling drugs--will they model the next 100? Nat Rev Drug Discov. 2003 Jan;2(1):38-51. | ||||
| Ref 535976 | Her2/neu is not a commonly expressed therapeutic target in melanoma -- a large cohort tissue microarray study. Melanoma Res. 2004 Jun;14(3):207-10. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.